Inactive Instrument

Radius Health, Inc. Share Price

Equities

RDUS

US7504692077

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Dynamic Chart
EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Radius Health, Inc for Binosto for the United States CI
Radius Health, Inc. Announces the Appointment of Al Medwar as Senior Vice President and Corporate Development CI
Radius Health, Inc. Appoints Erika Tooman as Senior Vice President/ General Counsel CI
Theramex Enters into an Exclusive Licensing Agreement with Radius Health Inc, to Commercialise ELADYNOS in the European Economic Area, United Kingdom, Australia and Brazil CI
Radius Health, Inc. announced that it has received funding from Webster Equity Partners, LLC CI
Radius Health's Tymlos® (Abaloparatide) Receives U.S. FDA Approval as A Treatment to Increase Bone Density in Men with Osteoporosis At High Risk for Fracture CI
Ambrx Biopharma Names Kate Hermans Interim CEO MT
Radius Health, Inc. Announces Board Changes CI
Radius Health, Inc. Enters into Credit Agreement CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from NASDAQ Composite Index CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P TMI Index CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P Global BMI Index CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P Biotechnology Select Industry Index CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from NASDAQ Biotechnology Index CI
Patient Square Capital, LP and Gurnet Point Capital Limited completed the acquisition of Radius Health, Inc. from Repertoire Partners LP, Velan Capital Investment Management LP and others. CI
More news
Managers TitleAgeSince
Chief Executive Officer - 11/10/22
Chief Tech/Sci/R&D Officer - 31/08/16
Investor Relations Contact - -
Members of the board TitleAgeSince
Chief Executive Officer - 11/10/22
Director/Board Member - -
Director/Board Member - 14/08/22
More insiders
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).
More about the company
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW